BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at assumed coverage on shares of BIOLASE (NASDAQ:BIOLFree Report) in a research note published on Thursday morning. The firm issued a sell rating on the medical technology company’s stock.

BIOL has been the topic of a number of other reports. Benchmark reiterated a speculative buy rating and set a $0.40 target price on shares of BIOLASE in a research note on Tuesday, May 14th. Maxim Group cut BIOLASE from a strong-buy rating to a hold rating in a research note on Friday, May 24th.

View Our Latest Research Report on BIOLASE

BIOLASE Price Performance

Shares of NASDAQ:BIOL opened at $0.14 on Thursday. The company has a current ratio of 1.17, a quick ratio of 0.64 and a debt-to-equity ratio of 34.06. The stock’s fifty day simple moving average is $0.16 and its two-hundred day simple moving average is $0.48. BIOLASE has a 1-year low of $0.13 and a 1-year high of $10.31. The stock has a market cap of $4.80 million, a PE ratio of -0.01 and a beta of 0.74.

BIOLASE (NASDAQ:BIOLGet Free Report) last released its earnings results on Monday, May 13th. The medical technology company reported ($0.36) EPS for the quarter. The business had revenue of $10.13 million for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 43.56%.

Institutional Investors Weigh In On BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC raised its stake in shares of BIOLASE, Inc. (NASDAQ:BIOLFree Report) by 1,068.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the quarter. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is owned by institutional investors.


(Get Free Report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.

Featured Stories

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with's FREE daily email newsletter.